
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 8.33333333333 | 1.2 | 1.45 | 1.19 | 428951 | 1.38922874 | CS |
4 | 0.21 | 19.2660550459 | 1.09 | 1.45 | 0.925 | 295548 | 1.22919347 | CS |
12 | -0.11 | -7.80141843972 | 1.41 | 1.45 | 0.7203 | 343718 | 1.10076567 | CS |
26 | -0.46 | -26.1363636364 | 1.76 | 2.0397 | 0.7203 | 230418 | 1.23447004 | CS |
52 | 0.61 | 88.4057971014 | 0.69 | 2.45 | 0.5116 | 302052 | 1.25386904 | CS |
156 | -1.27 | -49.4163424125 | 2.57 | 2.7171 | 0.5116 | 400368 | 1.27289871 | CS |
260 | -49.92 | -97.461928934 | 51.22 | 121.98 | 0.5116 | 468598 | 11.68835211 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions